Outset Medical reports Q2 EPS (90c) vs. (92c) last year

Reports Q2 revenue $36.0M vs. $25.1M last year. “Our momentum entering 2023 carried through the second quarter, led by the strong demand from hospitals due to the value realized from insourcing dialysis with Tablo,” said Leslie Trigg, Chair and Chief Executive Officer. “As important, Tablo’s unique ease of use and flexibility continues to drive patient interest and demand from home-care providers, including traditional acute-care providers.”